Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 36
- Registration Number
- NCT06067425
- Locations
- 🇮🇹
Investigational Site Number : 3800002, Milan, Lombardia, Italy
🇦🇺Investigational Site Number : 0360001, Parkville, Victoria, Australia
🇨🇳Investigational Site Number : 1560002, Shanghai, China
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT06064539
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 144
- Registration Number
- NCT06064526
- Locations
- 🇫🇷
Sanofi-Aventis, France, Chilly-Mazarin, France
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2075
- Registration Number
- NCT06059456
- Locations
- 🇫🇮
Investigational Site Number : 2460001, Helsinki, Finland
🇩🇪Investigational Site Number : 2760010, Martinsried, Germany
🇩🇪Investigational Site Number : 2760003, Martinsried, Germany
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT06058156
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Site Number: 8400006, Pittsburgh, Pennsylvania, United States
🇺🇸Wayne Health-Dearborn Site Number: 8400009, Dearborn, Michigan, United States
🇺🇸Encore Medical Research Site Number: 8400002, Boynton Beach, Florida, United States
Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan
- Conditions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT06052800
- Locations
- 🇨🇳
Investigational Site Number :1580001, Taipei, Taiwan
🇨🇳Investigational Site Number :1580003, Taipei, Taiwan
🇨🇳Investigational Site Number :1580002, Taipei, Taiwan
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
- Conditions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 900
- Registration Number
- NCT06039241
- Locations
- 🇩🇪
Investigational Site Number: 186, Karlsruhe, Germany
🇩🇪Investigational Site Number: 069, Köln, Germany
🇩🇪Investigational Site Number: 004, Berlin, Germany
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 380
- Registration Number
- NCT06033833
- Locations
- 🇧🇷
Hospital São Vicente de Paulo - Passo Fundo- Site Number : 0760001, Passo Fundo, Rio Grande Do Sul, Brazil
🇺🇸Bensch Research Associates- Site Number : 8400004, Stockton, California, United States
🇺🇸Helix Biomedics- Site Number : 8400029, Boynton Beach, Florida, United States
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 156
- Registration Number
- NCT06028230
- Locations
- 🇺🇸
Clear Dermatology & Aesthetics Center Scottsdale Site Number : 8400006, Scottsdale, Arizona, United States
🇺🇸First OC Dermatology Site Number: 8400007, Fountain Valley, California, United States
🇺🇸Encore Medical Research - Boyton Beach Site Number : 8400002, Boynton Beach, Florida, United States
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
- Conditions
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT06019728
- Locations
- 🇺🇸
Emory University School of Medicine Site Number : 1005, Atlanta, Georgia, United States
🇺🇸Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002, Fairfax, Virginia, United States
🇺🇸Infusion Associates Site Number : 1001, Grand Rapids, Michigan, United States